Indication

Renal Cell Carcinoma

Clinical and regulatory intelligence for Renal Cell Carcinoma with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 1
Assets: 1

Relevant assets

KEYTRUDA →

Relevant companies

Merck →

Recent signals(2)

ClinicalJune 17, 2026

Merck and Eisai's LITESPARK-012 Trial Fails to Meet Primary Endpoints in RCC

The Phase 3 LITESPARK-012 trial did not meet its dual primary endpoints of progression-free survival and overall survival for the evaluated combination therapies.

RegulatoryJune 13, 2026

FDA Approves KEYTRUDA Combinations for Adjuvant Treatment in Clear Cell RCC

The FDA has approved KEYTRUDA and KEYTRUDA QLEX in combination with WELIREG for adjuvant treatment in ccRCC patients, marking a significant advancement in therapy.

Upcoming catalysts(1)

Phase I Readout

CRISPR Therapeutics — CTX130

Allogeneic CAR-T early data tests off-the-shelf cell therapy viability in solid tumors.

June 22, 2026 · Phase I

Therapeutic areas

Oncology →

Renal Cell Carcinoma →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.